Statement by Ralph G. Neas, President and CEO, Generic Pharmaceutical Association, on FDA’s Acceptance of Sandoz Biologics License Application for Filgrastim Under the New Biosimilar Pathway

Published Online: Thursday, July 24, 2014
Follow Pharmacy_Times:
PRESS RELEASE

“For the first time, the FDA has accepted a filing for an approval of a biosimilar drug, a major step toward access for Americans to safe, effective alternatives to costly brand biologic medicines.

Biosimilars have been successfully used in Europe and other markets for years. Filgrastim’s filing acceptance moves us closer to the day when U.S. patients that currently must rely on costly brand biologics for treatment will have more choices for the medicine that they need.

This approval represents a new frontier — not only for patients, but for our nation’s health system. Express Scripts projects that the United States would save $250 billion between 2014 and 2024 if filgrastim and 10 other biosimilars would enter the market.

We look forward to the integration of biosimilar therapies into the American health system, and witnessing the realization of the transformative potential of these innovative therapies.”
Related Articles
After years of debate and regulatory hurdles, a milestone was achieved today when the FDA approved the first biosimilar in the United States.
Today, an expert panel at the 2015 Generic Pharmaceutical Association Annual Meeting, “FDA and Industry Perspectives on Quality Culture,” convened to discuss a shared commitment with industry to the highest standards of manufacturing quality and regulatory processes.
The Generic Pharmaceutical Association today announced the election of its 2015 Executive Committee and Board of Directors.
The Generic Pharmaceutical Association and its members applaud the significant progress made by the agency during Commissioner of Food and Drugs Dr. Margaret Hamburg’s six years leading the U.S. Food and Drug Administration. Throughout her tenure, Dr. Hamburg has been a tireless advocate for patient safety and a leader in efforts to assure that FDA decisions are guided by scientific principles.
Latest Issues
  • photo
    Pharmacy Times
    photo
    Health-System Edition
    photo
    Directions in Pharmacy
    photo
    OTC Guide
    photo
    Generic Supplements
  • photo
    Pharmacy Careers
    photo
    Specialty Pharmacy Times
    photo
    Generic
$auto_registration$